Development of COVID-19 vaccine using a dual Toll-like receptor ligand liposome adjuvant

Development of COVID-19 vaccine using a dual Toll-like receptor ligand liposome adjuvant

Abstract We developed a SARS-CoV-2 spike subunit vaccine formulation containing dual TLR ligand liposome adjuvant. The vaccine-induced robust systemic neutralizing antibodies and completely protected mice from a lethal challenge. Two immunizations protected against lung injury and cleared the virus...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Mayuresh M. Abhyankar, Barbara J. Mann, Jeffrey M. Sturek, Savannah Brovero, G. Brett Moreau, Anjali Sengar, Crystal M. Richardson, Sayeh Agah, Anna Pomés, Peter M. Kasson, Mark A. Tomai, Christopher B. Fox, William A. Petri
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Immunologic diseases. Allergy
RC581-607
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/da4da1c7c88a4956b31769225afbc2c2
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Abstract We developed a SARS-CoV-2 spike subunit vaccine formulation containing dual TLR ligand liposome adjuvant. The vaccine-induced robust systemic neutralizing antibodies and completely protected mice from a lethal challenge. Two immunizations protected against lung injury and cleared the virus from lungs upon challenge. The adjuvanted vaccine also elicited systemic and local anti-Spike IgA which can be an important feature for a COVID-19 vaccine.

Ejemplares similares